Mylan Places Big Bet On Antihypertensives: $4 Bil. Deal For King
Executive Summary
Mylan's proposed acquisition of King is a big move by the generic company to carve out a leading position in the branded antihypertensive market
You may also be interested in...
King Says It Can Grow On Its Own Following Collapse Of Mylan Merger Plans
King will not pursue a new merger partner following the collapse of its proposed agreement to be acquired by Mylan
King Says It Can Grow On Its Own Following Collapse Of Mylan Merger Plans
King will not pursue a new merger partner following the collapse of its proposed agreement to be acquired by Mylan
Mylan Unlikely To Crown King: $3.8 Bil. Bid In Jeopardy Over Restatement
Mylan said it is unlikely to complete its proposed acquisition of King, save a renegotiation of the terms of the deal